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Abstract
Interaction among different risk factors plays an important role in the development and progress of complex disease,
such as diabetes. However, traditional epidemiological methods often focus on analyzing individual or a few
‘essential’ risk factors, hopefully to obtain some insights into the etiology of complex disease. In this paper, we
propose a systematic framework for risk factor analysis based on a synergy network, which enables better
identification of potential risk factors that may serve as prognostic markers for complex disease. A spectral
approximate algorithm is derived to solve this network optimization problem, which leads to a new network-based
feature ranking method that improves the traditional feature ranking by taking into account the pairwise synergistic
interactions among risk factors in addition to their individual predictive power. We first evaluate the performance of
our method based on simulated datasets, and then, we use our method to study immunologic and metabolic indices
based on the Diabetes Prevention Trial-Type 1 (DPT-1) study that may provide prognostic and diagnostic information
regarding the development of type 1 diabetes. The performance comparison based on both simulated and DPT-1
datasets demonstrates that our network-based ranking method provides prognostic markers with higher predictive
power than traditional analysis based on individual factors.
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Introduction
Type 1 diabetes (T1D) is an autoimmune disorder and one
of the common pediatric diseases with a diverse patho-
genesis, clinical phenotype, and outcome [1]. Despite the
emergence of T1D as a global issue with a steady increase
in incidence worldwide over the past decade [2], the eti-
ology of T1D is still not fully understood. Recent studies,
including the Diabetes Prevention Trial-Type 1 (DPT-1)
[3], have suggested that this complex disease has multiple
risk factors, including genetic predisposition, diet, viruses,
and geography in addition to autoimmunity [1,4-7]. The
previous epidemiology studies mostly focus on studying
hypotheses regarding individual risk factors, which have
obtained important initial understanding, including the
predisposing roles from genetic markers such as human
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leukocyte antigens [5]. However, traditional hypothesis-
driven approaches focusing on ‘essential’ factors may not
be sufficient for fully understanding T1D [6]. With large-
scale perspective studies such as DPT-1, we believe that
data-driven investigation considering all candidate factors
with their interactions can serve as a critical complement
for previous hypothesis-driven research.
Data-driven methods have been proven to be useful in
both identifying probable mechanisms involved in disease
and providing accurate biomarkers for early prediction
[8,9]. However, as shown in genome-wide association
studies (GWAS), single marker analysis is not sufficient
for genetic studies of complex diseases [10,11]. In order
to better explain the missing heritability of complex
disease through analyzing high-dimensional genotype
data, several methods have been proposed to take into
account the interactive effect among single-nucleotide
polymorphisms as well as multiple genes in GWAS and
other -omic data analysis [12-14]. In this work, we
propose a network-based mathematical model for sys-
tematically analyzing candidate risk factors for disease.
We consider that the individual effect and interactions
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from potential risk factors are all manifested as statis-
tical associations with the disease outcome. Based on
this, we construct a synergy network which integrates
both the individual and synergistic interactive effects
of factors in one single graph structure. We then pro-
pose a novel algorithm based on this synergy network
to identify biomarkers for early prediction of disease.
Specifically, we verify the effectiveness of our method
using simulated case-control datasets. With such vali-
dated results, we apply our method to identify biomarkers
for prognosis of T1D from measured immunologic and
metabolic indices in DPT-1. The performance of the iden-
tified markers is then compared to the performance of
traditional forward feature selection which only consid-
ers the individual statistical association with outcome.
Our comprehensive results show that our network-based
method identifies better biomarkers with better predictive
performance.
Methods
Feature selection approaches are commonly used to iden-
tify biomarkers by finding a subset of biomedicalmeasure-
ments with high predictive power with respect to disease
outcome [15-17]. As it is computationally very expen-
sive to exhaustively search for the best subset of vari-
ables, these methods mostly rely on heuristic approaches.
Filtering variables based on their individual effect on dis-
ease outcome has been a common practice in biomedical
research. Heuristic approaches based on filtering have
been successful in identifying biomarkers with strong
individual effects. However, they may miss variables with
weak individual effects but having synergistic interactive
effects that produce high predictive accuracy [15,17]. To
avoid missing these critical variables with high syner-
gistic effects on outcome, we propose a new approach
which takes into account both individual and synergis-
tic interactive effects. In our approach, we first construct
a synergy network based on the individual and synergis-
tic effects of all the observed variables. Then, we solve
the problem of finding the best subnetwork by an effi-
cient graph spectral algorithm which leads to a novel
feature ranking that improves the traditional ranking
by taking into account the interaction among variables.
Finally, we use this feature ranking together with tradi-
tional forward feature selection to achieve the final set of
biomarkers.
Synergy network
To construct the synergy network, we need to measure
the individual predictive power of all variables together
with their pairwise synergistic power. One natural way to
measure both individual and synergistic powers is to use
a logistic regression model. In order to measure the indi-
vidual power of variable vi, we can learn the following
logistic model log(g/(1 − g)) = α0 + α1vi in which g is
the probability p(y = 1|vi), where y denotes the disease
outcome of interest. After fitting this model to the given
data, the magnitude of the coefficient α1 measures the
individual power of vi. To make sure that the measure-
ments for different variables are with the same unit and
comparable to each other, we use − log(pi) as the indi-
vidual power of variable vi, in which pi is the coefficient
p-value for α1 and measures the statistical significance of
the individual power of vi. Similarly, in order to measure
the synergistic predictive power between two variables vi
and vj, we fit the following logistic model log(g/(1− g)) =
α0 +α1vi +α2vj +βvivj (where g = p(y = 1|vi, vj)) to data
and consider − log(pij) as the synergistic power of vari-
ables vi and vj, in which pij is the coefficient p-value of β .
With that, we construct the synergy network which can be
represented by a graphG(V ,E). In this synergy network,V
is the set of nodes corresponding to all the variables, and
each vi ∈ V has the node weight f (vi) equal to − log(pi);
E is the set of edges (vi, vj) with the edge weight s(vi, vj)
equal to − log(pij).
Finding subnetworks for biomarker identification
As explained, the synergy network integrates both indi-
vidual and synergistic powers of candidate risk factors
in a single graph structure. Similar to the traditional
problem of feature selection, here we are looking for
subsets of risk factors or subnetworks in the synergy
network, with the highest possible discriminative power
regarding disease outcome y. To simplify the problem,
we approximate the discriminative power of subnet-
works by the summation of the node weights and edge
weights induced in them. We note that this approxi-
mation is expected to perform better than traditional
feature selection approaches based on only individual
effects [16] due to the integration of synergistic effects in
our synergy network. The biomarker identification prob-










where C denotes potential subnetworks and 0 ≤ λ ≤ 1
is a weighting coefficient between individual and syner-
gistic effects. As both f (vi) and s(vi, vj) are nonnegative,
the previous optimization problem has the degenerated
solution to include all the risk factors in C. To overcome
this problem, we further impose another constraint to
restrict the size of selected subnetworks to have |C| ≤
K . This formulation is in fact the problem of finding a
maximumweighted clique (MWCP) [18] which is a gener-
alization of the classical maximum clique problem (MCP).
As MCP is nondeterministically polynomial (NP)-hard
[19], it can be easily shown that MWCP is NP-hard as
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well. Thus, our biomarker identification problem formu-
lated in Equation 1 is also an NP-hard problem. Sev-
eral approaches have been previously proposed to find
the exact optimal solution of the problem by employing
branch-and-bound techniques, but it is probable that
exhaustive search over all possible subnetworks is needed
[18]. In this paper, we propose a fast approximate algo-
rithm for MWCP which also provides a ranked list of
features based on both their individual and synergistic
effects.
Feature ranking by a graph spectral algorithm
We first rewrite the optimization problem given in
Equation 1 as a quadratic integer programming prob-
lem as follows: For each node vi in G, we consider an
integer variable xi which is equal to 1 if the node vi is
selected in the subnetwork C and is 0 otherwise. Using
this variable, we can rewrite Equation 1 as maxx =
[x1, x2, . . . xn]T
∑n
i=1 f (vi)x2i + λ
∑n
i,j=1 s(vi, vj)xixj, where
n is the number of feature nodes in G. We fur-
ther define the matrix M(n×n) with diagonal entries
Mi,i equal to the individual power f (vi), and off-
diagonal entries Mi,j equal to the synergistic power
λ × s(vi, vj). We can rewrite the optimization prob-




s.t. xTx ≤ K ;
xi ∈ {0, 1},
in which x = [x1, · · · , xn]T is a binary integer vector. In
fact, the size constraint is equivalent to putting in a sparse
penalty on x to select the smallest number of risk fac-
tors that have high predictive power. In order to solve this
constrained quadratic integer programming problem, we
develop a spectral approximate algorithm. We first relax
the integer variable xi ∈ {0, 1} to xi ∈ R. Then, using
Lagrangian relaxation, we can transform the original opti-
mization problem given in Equation 2 to the following
quadratic programming optimization problem:
maxx x
TMx + α(K − xTx), (3)
where α is the Lagrangian multiplier. Based on the
Karush-Kuhn-Tucker condition [20], the optimal solution
of this relaxed quadratic programming problem has to
(necessarily) satisfy the condition that the derivative of the




xTMx + α(K − xTx)
]
= 0. (4)
By straightforward algebraic manipulations, we can
show that the potential solution x∗ has to satisfy Mx∗ =
αx∗. Therefore, the relaxed solution x∗ to the MWCP is
an eigenvector of the matrix M. Furthermore, we want
the objective function x∗TMx∗ = αx∗Tx∗ = αK to have
the maximum value with x∗, which means that we want
α to be as large as possible. Hence, the solution x∗ will
be the eigenvector of M with the largest corresponding
eigenvalue. Also given the relaxed solution x∗, for any K,
the approximate solution to the original integer program-
ming optimization problem is to take topK nodes with the
largest corresponding magnitudes in x∗. This also shows
that the candidate risk factors with larger magnitudes in
x∗ are more desirable to be selected in the final subset
of risk factors as potential prognostic biomarkers. Thus,
we can use the absolute values in x∗ as a score to rank
the risk factors. We note that K can be an arbitrary num-
ber without loss of generality, which will not affect our
final ranking as the x∗ only depends on the matrix M. As
one can see, the proposed method combines both individ-
ual power and synergistic power among all candidate risk
factors into one single score that can be used to rank them.
Biomarker identification using network-based
spectral ranking
In order to select a subset of risk factors based on any
ranking, a common approach is to use forward feature
selection [16]. We replace the ranking step of the forward
feature selection, which is only based on individual power,
by our network-based spectral ranking which takes into
account the interaction among factors as well. In forward
feature selection, we sequentially add potential risk factors
from the top of the ranked list to the current set of selected
factors only if it improves the classification performance;
otherwise, we move to the next factor in the ranked list.
This procedure is repeated until we reach the end of the
ranked list.
Experiments and discussions
We evaluate the performance of our network-based
biomarker identification based on both simulated datasets
and datasets obtained from the DPT-1 study and com-
pare it with the individual-based biomarker identification,
which only considers individual effects. In order to prop-
erly estimate and compare the performance of biomarker
identification methods, we perform an ‘embedded’ cross-
validation procedure.
Performance evaluation procedure
As explained earlier, our feature selection approach
includes two steps: First, we construct a synergy network
based on the given dataset and rank the candidate risk
factors using our spectral algorithm. Second, we use the
ranked list of factors obtained in the first step to perform
a forward feature selection [16]. To make sure that we do
not overestimate the performance of our biomarker iden-
tification approach, we perform the following embedded
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cross-validation procedure: Similar to the regular ten-fold
cross validation, we first randomly divide the dataset into
ten folds, within which one fold is used as the testing set
to test the performance and the remaining nine folds are
used as the training set to select biomarkers and learn the
classifier. In order to select biomarkers based on the train-
ing set, we first use all the data points in the training set
to construct a synergy network and perform our spectral
algorithm to obtain the ranked list. Then, using the ranked
list, we perform a forward feature selection method to
select the best performing set of biomarkers. In the for-
ward feature selection method, we sequentially add can-
didate factors to the current feature set (starting with an
empty set), if it improves the classification performance;
otherwise, wemove to the next factor in the ranked list. To
evaluate the performance of a set of potential risk factors
during forward feature selection, we use another standard
ten-fold cross validation in which we further divide the
training set into ten folds, nine of which are used to train
the classifier and the remaining is used to test the per-
formance. After performing the forward feature selection
and identifying the biomarkers, we learn a classifier based
on the training dataset using those selected features and
compute the performance based on the testing set. Dur-
ing our performance evaluation procedure, we adopt the
MATLAB implementation of quadratic discriminant anal-
ysis as the classifier [21] to make sure that the pairwise
interaction among risk factors is taken into account by the
classifier. To measure the performance of any classifier in
our performance evaluation procedure, in addition to the
accuracy, we also compute the area under the ROC curve
(AUC) which is a more reliable measure of prediction per-
formance [22] in our experiments. When we use accuracy
as the performance measure during forward feature selec-
tion, the identified biomarkers are optimized to provide
better accuracy. We also take AUC as the performance
measure for forward feature selection so that the biomark-
ers are optimized to provide better AUC. This two sets of
biomarkers are not necessarily the same, especially with
unbalanced datasets, as they are supposed to optimize
for different criteria. Thus, for each dataset, we have two
sets of results: one based on accuracy and one based on
AUC.
Performance comparison based on the simulated datasets
We simulate a case-control disease model, in which the
outcome y (disease) follows a Bernoulli distribution with
the success parameter equal to p( y = 1|v) given the input
variables v. We first simulate 30 random variables as input
variables v =[v1, v2, . . . , v30]T . From all 435 potential pairs
of these randomly simulated variables, ten of them are
randomly selected to have synergistic effects with respect
to the outcome. Based on this, we follow the following
logistic model to simulate the disease outcome y:
log
( p( y = 1|v)










In this logistic model, the magnitude of each individual
coefficient αi determines the individual effect of the cor-
responding variable vi on outcome y, and the magnitude
of the interaction coefficient βij determines the amount
of synergistic effect of two variables vi and vj on the out-
come. To obtain the previously described case-control
data, we simulate 30 random features with each variable vi
following a mixture-of-Gaussian distribution with equally
weighted (mixture parameters equal to 0.5) Gaussian dis-
tributions with the same variance of 1.0 and the means
equal to −1.0 and 1.0, respectively. For 435 interaction
coefficients βij, we randomly set 425 of them to zero, and
the values of the other ten are drawn from the standard
normal distribution (mean 0.0 and variance 1.0). We also
set all the individual coefficients αi to zero which means
that there is no feature with significant individual effect.
To simulate the outcome y, we first compute the prob-
ability p(y = 1|v) based on the previous logistic model
(Equation 5). Then, we generate the value for y from a
Bernoulli distribution with the success parameter equal to
p( y = 1|v). We have generated 20 of such case-control
datasets with 200 data samples in each set for the perfor-
mance evaluation of our method. In order to make sure
that our performance comparison results are independent
of howwe set the values of these coefficients, each of these
20 datasets is simulated with different random values for
coefficients βij.
To demonstrate the advantage of our network-based
feature ranking, we compare the performance of our rank-
ing with the traditional individual-based feature ranking.
We use our embedded cross-validation procedure to eval-
uate the performance of both network-based ranking and
individual-based ranking. We repeat the embedded cross
validation 100 times for both individual- and network-
based rankings and calculate the average accuracy and
AUC for both methods. The performance comparison
for our 20 simulated datasets is shown in Figure 1.
The average accuracy and average AUC of our network-
based method among 20 datasets are 65.17% and 0.6518,
respectively, compared to 55.74% and 0.5577 obtained by
individual-based ranking. As expected, the performance
of our network-based ranking is significantly better than
individual-based ranking. This clearly shows that filtering
methods based on individual ranking are unable to cap-
ture those risk factors with synergistic effects but weak
individual effects, which are critical biomarkers for better
prediction.
In order to further show that our network-based
method does not only bias toward risk factors with


































Figure 1 Performance comparison between individual-based and network-based ranking for 20 simulated datasets. Note that we have
weak individual effects and significant synergistic effects in this ensemble of datasets.
only synergistic effects, we further check the perfor-
mance of our network-based ranking when there are
risk factors with significant individual effects in the
case-control disease model. We use the same logistic
regression model in Equation 5 where in addition to 10
nonzero interaction coefficients βij, we also have five
random nonzero individual coefficients αi (α0 is set to
zero as well). The values for those nonzero αi are also
drawn from a standard normal distribution. We have
also generated 20 datasets of this new model, each with
200 samples. Similar to the previous 20 datasets, each
of these 20 datasets is simulated with different ran-
dom values for coefficients αi and βij. The performance
evaluation results based on these 20 new simulated
datasets are shown in Figure 2. The average accu-
racy and average AUC obtained by our network-based
method among these 20 new datasets are 65.47% and
0.6536, respectively, both of which are significantly higher
than 60.38% and 0.6040 obtained by individual-based
ranking. This shows that our network-based ranking
consistently performs better than individual ranking
even when there are features with significant individual
effects.
Finally, in our simulation model, we always have p( y =
1) = p( y = 0), which is due to the symmetry of the logis-
tic function, symmetry of distribution of all features, and
symmetry of distribution of coefficients around zero. As
a result, the datasets simulated from the model are bal-
anced, i.e., they have almost the same number of case and
control samples. Because of this, the accuracy and AUC
performance measures are very similar for all of our simu-
lated datasets which might not be the case for unbalanced
datasets.
Biomarker identification in DPT-1
DPT-1 was a study designed to determine if T1D can be
prevented or delayed by preclinical intervention of insulin
supplement. It focuses on first- and second-degree non-
diabetic relatives of patients with T1D before the age of
45, since they have more than tenfold risk of develop-
ing T1D compared to the general population [3]. DPT-
1 screened 103,391 subjects altogether and categorized


































Figure 2 Performance comparison between individual-based and network-based ranking for the other 20 simulated datasets. Note that
we have both significant individual effects and significant synergistic effects in this ensemble.
them into four risk groups based on genetic susceptibil-
ity, age, the presence of autoantibodies (including islet cell
autoantibodies (ICA), insulin autoantibodies (IAA), glu-
tamic acid decarboxylase (GAD), insulinoma-associated
protein 2 (ICA512)), and the change of metabolic markers
during oral glucose tolerance test (OGTT) and IV glu-
cose tolerance test (IVGTT). The 3,483 subjects positive
for ICA were staged to quantify the projected 5-year risk
of diabetes [7]. Our analysis focuses on the study for the
‘high risk’ and ‘intermediate risk’ groups [7-9], which con-
tain 339 and 372 subjects, respectively. The subjects of
each group were randomly divided into two roughly equal
subgroups: one received parenteral or oral insulin supple-
ment, while the other was assigned to the placebo arm of
the study. In this paper, we focus on the subjects of the
placebo group.We consider the placebo subgroups of both
high-risk and intermediate-risk groups as a dataset for our
data-driven analysis (analysis based on the treated group
is provided in Additional file 1). The dataset contains
the following 19 features from baseline characteristics in
DPT-1, focusing on immunologic and metabolic mark-
ers. We have taken the available titer values for different
autoantibodies, including ICA, IAA, GAD, ICA512, and
micro-insulin autoantibodies. For metabolic indices, we
have fasting glucose, glycated hemoglobin (HbA1c), fast-
ing insulin, and first-phase insulin response (FPIR) from
IVGTTs. Homeostasis model assessment of insulin resis-
tance (HOMA-IR) and FPIR-to-HOMA-IR ratio are also
computed as in [9]. From OGTTs, in addition to 2-h
glucose and fasting glucose, we have collected blood sam-
ples for C-peptide measurements in the fasting state and
then 30, 60, 90, and 120 min after oral glucose, from
which we have computed peak C-peptide as the max-
imum point of all measurements and AUC C-peptide
using the trapezoid rule. Furthermore, as age and body
mass index (BMI) have been conjectured to be impor-
tant confounding factors, we also include them in our
set of features. We are interested in identifying the
most predictive group of features as biomarkers from
the above described candidates to predict the outcome
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Table 1 Accuracy and AUC performance of network-based




Individual ranking Network-based ranking p-value
Accuracy 68.31% 69.14% 6.8e−04
AUC 0.6524 0.6724 7.17e−11
which is the development of T1D at the end of the DPT-
1 study. The dataset contains 356 subjects within which
133 subjects developed T1D at the end of the study.
To check the performance of our network-based
biomarker identification for DPT-1, similar to simulated
datasets, we repeat the embedded cross validation 100
times and use the average performance. In order to show
the advantage of our network-basedmethod, we also com-
pute the performance of individual-based feature ranking.
The results based on both accuracy and AUC measure-
ments are given in Table 1. As one can see, both accuracy
and AUC obtained by our network-based ranking are
significantly higher than individual-based ranking with p-
values of 6.8e−04 and 7.17e−11, respectively. The results
obtained based on both simulated and DPT-1 dataset
clearly show that our spectral network-based feature rank-
ing provides biomarkers with significantly better predic-
tive power than individual-based feature ranking. This
also verifies our expectation that the integration of syn-
ergistic interaction among features provides biomarkers
with higher prediction accuracies.
In each run of the embedded ten-fold cross validation
procedure, we in fact have ten possibly different sets of
selected features as we perform feature selection for each
fold based on a different subset of training samples at
each run of the cross-validation procedure. By repeating
this procedure 100 times, we obtain 1,000 (100×10) dif-
ferent subsets of biomarkers. In order to report a single
reliable set of biomarkers, we first compute the frequency
of the appearance of each feature and then select the
features that at least appeared in 40% of the 1,000 (i.e.,
400) selected subsets. The single set of biomarkers based
on both individual and network-based rankings is pro-
vided in Table 2. We have also evaluated the performance
of those final biomarkers by 100 repeated ten-fold cross
validations. Their corresponding accuracies and AUCs are
also given in Table 2.
Note that, as mentioned previously, the features selected
during the forward feature selection step of our biomarker
identification method might vary when we optimize dif-
ferent performance measures. As a result, the final set
of biomarkers when we use accuracy in our performance
evaluation is different from the final set of biomarkers
when we use AUC. The final set of biomarkers using
both accuracy and AUC is reported; however, based
on the fact that AUC measurement is more reliable
than accuracy for unbalanced datasets, we believe that
the final set of biomarkers obtained by AUC is more
reliable.
Due to the relatively small number of features in this
study, it is feasible to perform an exhaustive search over
all possible subsets of features to find the biomarker
set with the best performance. We computed the AUC
and accuracy of all 219 − 1 possible subsets based on
100 repeated ten-fold cross validations. The best per-
forming subsets together with their corresponding mea-
sured performances are also given in Table 2. The results
in Table 2 clearly show that the network-based fea-
ture ranking method provides more predictive biomark-
ers than the individual-based feature ranking which are
Table 2 Final sets of biomarkers and their corresponding accuracy and AUC performances for the DPT-1 dataset
Performance Individual Network-based Exhaustive
Measure ranking ranking search




70.59% 2-h glucose, IAA, fasting glucose (IVGTT),
ICA512, peak C-peptide, AUC C-peptide,
FPIR-to-HOMA-IR ratio













0.6779 2-h glucose, IAA, FPIR, fasting glucose
(IVGTT), ICA512, peak C-peptide, AUC
C-peptide, FPIR-to-HOMA-IR ratio







Individual ranking, network-based ranking, and exhaustive search methods were used.







Peak C-Peptide AUC C-Peptide
FPIR-to-HOMA-IR ratio
Height Fasting glucose (IVGTT)
Weight
Fasting glucose (OGTT)
Fasting insulin (IVGTT) HOMAIR
HbA1c GAD MIAA





Figure 3 The average synergy network for the Placebo group in the DPT-1 dataset.
closer to the best performing biomarkers by exhaus-
tive search. Furthermore, the average of 1,000 synergy
networks obtained from 100 ×10 generation of syn-
ergy network in our embedded cross-validation procedure
is provided in Figure 3. This synergy network shows
that the nodes ‘FPIR-to-HOMA-IR ratio’, ‘fasting glu-
cose (IVGTT)’, and ‘ICA’ are important nodes with high
centrality in the average synergy network. From those
three risk factors, FPIR-to-HOMA-IR ratio and fasting
glucose (IVGTT) are also among the best biomarkers.
This again verifies the effectiveness of our systematic
network-based analysis in identifying important factors.
Furthermore, as shown in Table 2, our network-based
biomarker identification has successfully identified both
of those important biomarkers, while the individual-based
feature ranking has ignored them. We further provide
in Figure 4 the Venn diagrams of selected biomark-
ers which show the intersection of biomarkers selected
by different methods. As one can see, the intersection
between biomarkers selected by our network-based rank-
ing and best possible performing biomarkers is larger
than the intersection between biomarkers selected by
individual-based ranking and the best possible performing
biomarkers.
Conclusions
We have proposed a new feature ranking method that
significantly improves the traditional feature ranking by
considering the synergistic interaction among poten-
tial risk factors. The comprehensive results based on
simulated datasets and the dataset from DPT-1 have
shown that our network-based feature ranking can
help identify more predictive biomarkers than tradi-
tional individual-based feature ranking. The set of final
biomarkers identified for T1D may help find more pre-
dictive models for T1D which may provide early pre-
diction of disease for timely treatment. Furthermore,
the improvement obtained by our network-based data-
driven method suggests that a more comprehensive
systematic data-driven analysis of biomedical variables
























Figure 4 Venn diagrams illustrating the identified biomarkers using different methods. (A) Biomarkers identified by optimizing accuracy.
(B) Biomarkers identified by optimizing AUC.
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Additional file
Additional file 1: Supplementary material. The results for
network-based analysis based on the treated subjects from DPT-1 as well
as a stability analysis for λ are provided in this file.
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